News | August 14, 2024
Marksans Pharma Q1 FY25 revenue up 18%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals
This project is supported by the Irish Government through IDA Ireland
Morepen Labs successfully raised Rs. 200 Crore through QIP
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
Subscribe To Our Newsletter & Stay Updated
